Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia

Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease

Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved

Idorsia announces financial results for the first quarter 2018

Idorsia issues invitation to 2018 Annual General Meeting of Shareholders

Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development

Idorsia forms research collaboration with Roche in the field of cancer immunotherapy

Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)

Idorsia announces financial results as of 30 September 2017

Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company

ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

Idorsia - Reaching out for more